Omnicell, Inc. · NASDAQ:OMCL
Omnicell — Q3 2025 Earnings Presentation
35 slides from Omnicell's earnings presentation, Oct 30, 2025
Slide 1: Investor Presentation
Investor Presentation October 30, 2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of federal securities laws. These forward-looking statements include statements with respect to 2025 guidance, strategic and growth opportunities, other expectations and other non-historical informa
Slide 3: Our Purpose and Guiding Principles
Investor Presentation – October 30, 2025 Our Purpose Our Guiding Principles To be the healthcare Our Guiding Principles represent what we providers’ most trusted stand for as a company, guiding us in every partner to enable the aspect of how we do business. Autonomous Pharmacy transformation o Passi
Slide 4: Omnicell Investment Highlights
Investor Presentation – October 30, 2025 Omnicell Investment Highlights A recognized leader in medication management with a 30-year track record and an installed base that includes more than one-half of the top 300 U.S. health systems* Investing in SaaS and Expert Services (formerly Advanced Service
Slide 5: Omnicell's Growth Strategy
Investor Presentation – October 30, 2025 Omnicell’s Growth Strategy is to: CONNECT the health network DISRUPT Pharmacy care with innovation GROW where care is being delivered © 2025 Omnicell, Inc. 5
Slide 6: Our Strategy
Investor Presentation – October 30, 2025 Our Strategy Omnicell is transforming pharmacy care through outcomes-centric solutions combining robotics and smart devices, software workflows, expert services, and analytics designed to optimize clinical and business outcomes across all settings of care. HE
Slide 7: The Autonomous Pharmacy
Investor Presentation – October 30, 2025 The Autonomous Pharmacy Industry-Defined Vision Replace manual, error-prone activities with automated processes that are designed to be safer and more efficient. o Zero medication errors o Zero medication waste o Zero human touches until delivery to patient o
Slide 8: Delivering Solutions Designed to Support Customer Operational and Economic Environments
Investor Presentation – October 30, 2025 Delivering Solutions Designed to Support Customer Operational and Economic Environments CHALLENGE OUTCOME DELIVERED Barcode scanning through Central 25,000 Errors Annually in Hospitals 1 100% Pharmacy robotics supports enhanced safety and accuracy 5 Reduced 5
Slide 9: Revenue Growth Drivers
Investor Presentation – October 30, 2025 Revenue Growth Drivers Deep Customer Relationships Multiple Growth and Robust Backlog Drivers o Strong position with more than one- o Expanding Our Market Presence half of the top 300 U.S. health Expanding our footprint within our systems existing customer ba
Slide 10: SaaS and Expert Services Recurring Revenue Highlights
Investor Presentation – October 30, 2025 SaaS and Expert Services* SaaS and Expert Services Recurring Revenue Highlights Potential Revenue Opportunity SaaS and Expert Services as % of Total Revenue o Leveraging established channels and strong customer relationships Targeting 22% of total revenue for
Slide 11: Why We Believe Omnicell is Positioned to Win
Investor Presentation – October 30, 2025 Why We Believe Omnicell is Positioned to Win Omnicell has the right Omnicell has a proven Omnicell is scaling SaaS Continued investment in solutions and the right track record of innovation and Expert Services* to new products and business model to solve as t
Slide 12: Product Overview
Product Overview
Slide 13: Points of Care
Investor Presentation – October 30, 2025 Points of Care As the final step in the pharmaceutical administration process, the bedside exchange of medication from nurse to patient is critical to care success. However, countbacks, restocks, reconciliation, and other manual tasks may force nurses to spen
Slide 14: Central Pharmacy
Investor Presentation – October 30, 2025 Central Pharmacy Central pharmacy is the medication dispensing hub of most hospitals. Roadblocks that surface here have the potential to impact patient safety, care, and clinical workflows throughout the health system. Omnicell automates manual dispensing tas
Slide 15: IV Room
Investor Presentation – October 30, 2025 IV Room Accuracy and sterility in IV compounding are paramount to patient safety, but an overreliance on 503B outsourcing and manual in-house systems often creates unnecessary risk and expense. Omnicell’s advanced automation tools including sterile compoundin
Slide 16: Specialty Pharmacy
Investor Presentation – October 30, 2025 Specialty Pharmacy As medical innovations create new, more complex drugs, many pharmacies need specialized tools and expertise to help manage the patient’s treatment journey. Opening or optimizing an in-house specialty pharmacy often requires unique capabilit
Slide 17: Ambulatory Care – EnlivenHealth
Investor Presentation – October 30, 2025 Ambulatory Care – EnlivenHealth® Optimizing a patient’s medication journey often means extending care beyond the inpatient setting and enhancing the processes of retail and community pharmacies. Through EnlivenHealth®, Omnicell provides patient engagement sof
Slide 18: Ambulatory Care – Medication Adherence
Investor Presentation – October 30, 2025 Ambulatory Care – Medication Adherence Through industry-leading packaging and automation solutions, Omnicell Medication Adherence helps to empower pharmacies to work more efficiently as they seek to and improve medication safety and effectiveness for customer
Slide 19: Omnicell's Suite of SaaS and Expert Services
Investor Presentation – October 30, 2025 Omnicell’s Suite of SaaS and Expert Services* Varying combinations of robotics and smart devices, software workflows, expert services, and analytics that are designed to deliver outcomes in each setting of care where medications are managed IV Compounding Cen
Slide 20: Omnicell 2024 Innovation
Investor Presentation – October 30, 2025 Omnicell 2024 Innovation OmniSphere XT Amplify Central Med Automation Service OmniSphere April 2024 August 2024 December 2024 Innovative suite of solutions A complete solution combining Next-generation, cloud native, designed to enhance pharmacy robotics and
Slide 21: Central Med Automation Service
Investor Presentation – October 30, 2025 Central Med Automation Service A powerful solution designed to ensure your pharmacy operations excel today and evolve seamlessly into the future. Robotics and Smart Devices Transforming Software Pharmacy Care Expert Services © 2025 Omnicell, Inc. 21
Slide 22: OmniSphere
Investor Presentation – October 30, 2025 OmniSphere OmniSphere is a next-generation, cloud native, software workflow engine and data platform. This groundbreaking new platform, designed to leverage the full power of a cloud native architecture, seamlessly integrates robotics and smart devices to sup
Slide 23: Third Quarter 2025 Financial Highlights
Third Quarter 2025 Financial Highlights
Slide 24: Financial Snapshot
Investor Presentation – October 30, 2025 Financial Snapshot Q3 ’25 YoY Change Total Revenues $311 million 10% Non-GAAP Gross Margin % 44.2% (30 bps) Non-GAAP Operating Expenses $110 million 9% Non-GAAP EBITDA $41 million 6% Non-GAAP Diluted Earnings Per Share $0.51 ($0.05) See Appendix for a reconci
Slide 25: Total Year Revenue Composition
Investor Presentation – October 30, 2025 Total Year Revenue Composition Recurring vs YoY Guidance GAAP ($Million) Non Category Actual 1Q25 Actual 2Q25 Actual 3Q25 Change % TY–2025 Recurring (Mid-Point) Connected Devices and Software Non 1 Product $120 $139 $152 Licenses Recurring $661–$666 5% Consum
Slide 26: Metrics for 2025
Investor Presentation – October 30, 2025 Metrics for 2025 o Our previous Bookings metric included Connected Devices and Software Licenses, SaaS and Expert Service* and Consumables. Previous Bookings Metric • Connected Devices and Software Licenses o For 2025, our Product Bookings metric consists of
Slide 27: 2025 Guidance
Investor Presentation – October 30, 2025 2025 Guidance Long-Term Value Creation Opportunities Q4–2025 TY–2025 o Strength in our flagship point-of- NEW: Product bookings1 Not guided $500–$550 million care connected devices and the ability to extend value for our NEW: ARR2 Not guided $610–$630 million
Slide 28: An Outcomes-Based Approach to ESG
Investor Presentation – October 30, 2025 An Outcomes-Based Approach to ESG 2024 Environmental o Continued our efforts to reduce our environmental footprint and energy consumption, realizing decreases in both ESG Report emissions and energy use Published fifth annual o Began a new climate risk assess
Slide 29: Appendix
Appendix
Slide 30: Reconciliation of GAAP to Non-GAAP
Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) Reconciliation of GAAP gross profit to non-GAAP gross profit: GAAP gross profit GAAP gross margin Share-based compensation expense Amortization of acquired intangibles Enlivenhealth rest
Slide 31: Tax effects footnote
© 2025 Omnicell, Inc. (a) Tax effects calculated for all adjustments except share-based compensation expense, using an estimated annual effective tax rate of 21% for both fiscal years 2025 and 2024. 31
Slide 32: EBITDA definition footnote
(b) Defined as earnings before interest income and expense, taxes, depreciation, amortization, and share-based compensation, as well as excluding certain other non-GAAP adjustments. © 2025 Omnicell, Inc. 32
Slide 33: Glossary of Terms
Investor Presentation – October 30, 2025 Glossary of Terms Product Bookings: (Metric for 2025): We define product bookings generally as the value of non-cancelable contracts for our connected devices and software licenses. We typically exclude freight revenue and other less significant items ancilla
Slide 34: Glossary of Terms Continued
Investor Presentation – October 30, 2025 Glossary of Terms Continued Product Backlog: (Metric for 2025): Product backlog is the dollar amount of product bookings that have not yet been recognized as revenue. A majority of our connected devices and software license products are installable and recogn
Slide 35: Omnicell